Nizatidine is a potent and selective antagonist of histamine H2 receptors used for treatment of stomach and intestine ulcers. Also, it was recommended as a component of combination therapy for cancer treatment. New data indicate that it can be repurposed to treat subtypes of clear cell renal cell carcinoma (ccRCC) in patients expressing certain isoforms of the pyruvate kinase muscle type. Additionally, nizatidine increases utrophin A levels in in C2C12 myoblasts (relevant to Duchenne muscular dystrophy).
Clear cell renal cell carcinoma (ccRCC) accounts for 70-80% of kidney cancer diagnoses and displays high molecular and histologic heterogeneity. Hence, it is necessary to reveal the underlying molecular mechanisms involved in progression of ccRCC to better stratify the patients
The Journal of pharmacology and experimental therapeutics, 239(2), 406-410 (1986-11-01)
Nizatidine (LY139037), a selective histamine H2-receptor antagonist, is a potent inhibitor of gastric acid secretion. It was 17.8 times as active as cimetidine on histamine (10(-5) M)-induced secretion from the isolated gastric mucosa of the bullfrog. Nizatidine was 8.9 times
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.